 LEXINGTON, Mass., May 10, 2021 PRNewswire -- LogicBio Therapeutics, Inc. Nasdaq:LOGC LogicBio or the Company, a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the quarter ended March 31, 2021 and provided a business update. 